2025-07-22T10:28:56-05:00 2024-10-31 410746749 CLIFTONLARSONALLEN LLP 420 SOUTH ORANGE AVENUE SUITE 900 ORLANDO FL 32801 990 2023-11-01 363719712 THE KIDNEY CANCER ASSOCIATION KIDN 8008509132 PO BOX 676226 DALLAS TX 75267 GRETCHEN E VAUGHAN PRESIDENT & CEO 8008509132 2025-07-09 1 1 TINA HENTON P00630282 4078021200 2025-07-09 2023 2025-03-06 01:10:19Z GRETCHEN E VAUGHAN PO BOX 676226 DALLAS TX 75267 16849534 0 X WWW.KIDNEYCANCER.ORG X 1990 IL A GLOBAL COMMUNITY DEDICATED TO SERVING AND EMPOWERING PATIENTS, AND LEADING CHANGE THROUGH ADVOCACY, RESEARCH, AND EDUCATION. 16 16 19 226 0 0 2903367 3468895 201993 249037 -824975 1191650 99254 32447 2379639 4942029 428470 387698 0 0 2398212 2669682 0 0 363660 1914527 2216230 4741209 5273610 -2361570 -331581 23797390 26510439 2468132 1672474 21329258 24837965 THE KIDNEY CANCER ASSOCIATION IS A GLOBAL COMMUNITY DEDICATED TO SERVING AND EMPOWERING PATIENTS, AND LEADING CHANGE THROUGH ADVOCACY, RESEARCH, AND EDUCATION IN ORDER TO BE THE UNIVERSAL LEADER IN FINDING THE CURE FOR KIDNEY CANCER. 0 0 1657564 EDUCATION - THE KIDNEY CANCER ASSOCIATION PROVIDES OPPORTUNITIES FOR PHYSICIANS, RESEARCHERS, ACADEMICS, AND INDUSTRY PROFESSIONALS FROM ACROSS THE GLOBE TO COME TOGETHER AND EXCHANGE IDEAS THAT WILL DIRECT THE FUTURE OF KIDNEY CANCER RESEARCH AND TREATMENT IN THE ULTIMATE PURSUIT OF A CURE. THE PRIMARY OPPORTUNITIES ARE DURING THE TWO ANNUAL SYMPOSIA, IKCS NORTH AMERICA AND IKCS EUROPE, HELD BOTH IN PERSON. IKCS MEETINGS PROMOTE LEARNING, NETWORKING, AND UNPARALLELED OPPORTUNITIES FOR MENTORSHIP AND COLLABORATION. 1391350 12698 262709 PATIENT SUPPORT AND ADVOCACY - THE KIDNEY CANCER ASSOCIATION SEEKS TO BE A SOURCE OF EDUCATION AND RESOURCES FOR PATIENTS, CAREGIVERS, AND ANYONE IMPACTED BY KIDNEY CANCER. THE KCA PROVIDES PATIENT RESOURCES FOR EACH STAGE OF THE KIDNEY CANCER JOURNEY INCLUDING OUR JUST DIAGNOSED TOOLKIT, PATIENT NAVIGATOR PROGRAM, VIRTUAL PATIENT SYMPOSIUM, KCA CONNECT, PATIENT ASSISTANCE FUND, AND EDUCATIONAL RESOURCES INCLUDING INFORMATION ON TREATMENTS, DRUGS, CLINICAL TRIALS, AND CAREGIVING TO NAME A FEW. 815824 375000 RESEARCH - THE KIDNEY CANCER ASSOCIATION IS COMMITTED TO SUPPORTING HEALTHCARE PROFESSIONALS, FOSTERING PROFESSIONAL COLLABORATION, AND FUNDING RESEARCH THAT ADVANCES OUR UNDERSTANDING OF KIDNEY CANCER. THE ORGANIZATION AWARDED GRANTS TO PHYSICIANS AND SCIENTISTS ENGAGED IN RESEARCH TARGETING EARLY DETECTION AND INNOVATIVE TREATMENTS FOR KIDNEY CANCER. 3864738 1 1 0 0 0 0 0 0 0 1 1 0 0 0 1 1 1 0 0 0 1 0 0 0 0 0 0 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 9 0 19 1 0 0 0 0 0 0 0 0 0 0 0 0 X 16 16 0 0 0 0 0 0 0 1 0 0 0 1 1 1 1 1 1 1 1 0 IL X NATHAN HAUBRICH 8008509132 2777 ALLEN PKWY HOUSTON TX 77019 BRADLEY LEIBOVICH MD BOARD CHAIR 1.00 X X 0 0 0 RYAN NATZKE VICE CHAIR 0.50 X X 0 0 0 JOEL STERN TREASURER 0.50 X X 0 0 0 TESSA CHURCHILL MD SECRETARY 0.50 X X 0 0 0 LAURENCE ALBIGES MD PHD DIRECTOR 0.50 X 0 0 0 MAHUL B AMIN MD DIRECTOR 0.50 X 0 0 0 NOAH BUNTMAN DIRECTOR 1.00 X 0 0 0 RONALD BUKOWSKI MD DIRECTOR 0.50 X 0 0 0 CRAIG DEPRIESTER DIRECTOR 0.50 X 0 0 0 DANIEL GEORGE MD DIRECTOR 0.50 X 0 0 0 JAMIE GRAVES DIRECTOR 0.50 X 0 0 0 DAVID PERRY ESQ DIRECTOR 0.50 X 0 0 0 SHELLEY ROBSON DIRECTOR 0.50 X 0 0 0 BRIAN SHUCH MD DIRECTOR 0.50 X 0 0 0 LAURA WOOD RN DIRECTOR 0.50 X 0 0 0 RUBEN YBARRA DIRECTOR 0.50 X 0 0 0 GRETCHEN VAUGHAN PRESIDENT & CEO 40.00 X 339752 0 26851 KENDALL MONROE CHIEF ADVANCEMENT OFFICER 40.00 X 238378 0 28538 SALVATORE LA ROSA CHIEF SCIENTIFIC OFFICER 40.00 X 213177 0 17180 LARANDA BURKE CHIEF FINANCIAL OFFICER 40.00 X 197400 0 25282 MICHAEL NATHAN HAUBRICH DIRECTOR OF FINANCE 0.50 X 0 0 0 RADHA CHITALE SR. DIRECTOR OF COMMUNICATIONS 40.00 X 115359 0 16343 ANGELA WASHINGTON DIRCTOR OF OPERATIONS 40.00 X 114633 0 16307 1218699 0 130501 6 0 1 0 JEANETTE STERNSGAARD 27022 DAVIES AVE AURORA CO 80016 EVENT PLANNING 147886 1 3468895 9773 3468895 SYMPOSIA REGISTRATIONS 611710 249037 249037 249037 749101 749101 12344787 11902238 442549 442549 442549 18939 5267 13672 13672 MISCELLANEOUS INCOME 900099 18820 18820 LOSS ON EXCHANGE RATES 900099 -45 -45 18775 4942029 262709 0 1210425 X 375000 375000 12698 12698 1100879 860299 99916 140664 1196584 773137 332993 90454 49147 30041 17856 1250 174610 112025 42340 20245 148462 104323 30670 13469 16826 16826 24042 24042 42831 42831 530716 343699 151094 35923 68529 34870 2365 31294 62296 24645 36194 1457 282483 135323 135106 12054 60996 60996 173113 140380 20653 12080 24361 19157 4846 358 2327 1048 1134 145 12652 625 12027 EDUCATION PROGRAMS 806834 806834 PATIENT PROGRAMS 66975 66975 RESEARCH EXPENSES 22912 22912 LICENSE & PERMITS 12199 12199 6138 747 1124 4267 5273610 3864738 1045212 363660 52700 589406 1510000 1274647 16903 114597 357472 299537 16287 10471 8143 5816 21195632 23548084 656540 678352 23797390 26510439 391505 377475 500000 1418160 1146878 158467 148121 2468132 1672474 X 20737858 23684171 591400 1153794 21329258 24837965 23797390 26510439 X -331581 3791571 48717 X 0 1 X 1 0 X 770325 2826146 2818520 2903367 3468895 12787253 770325 2826146 2818520 2903367 3468895 12787253 3359648 9427605 738200 463048 703006 678656 749101 3332011 1405 251669 7015 100633 18775 379497 16498761 950986 0.57140 0.56940 X SCHEDULE A, PART II, LINE 10, EXPLANATION OF OTHER INCOME: OTHER GROSS INCOME - 2019 AMOUNT: $ 1,405. 2020 AMOUNT: $ 251,669. 2021 AMOUNT: $ 9,657. 2022 AMOUNT: $ 108,486. 2023 AMOUNT: $ 18,820. LOSS ON EXCHANGE RATES - 2021 AMOUNT: $ -2,642. 2022 AMOUNT: $ -7,853. 2023 AMOUNT: $ -45. RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 17027165 285616 4234722 386210 600000 20561293 16678507 36208 1137450 375000 450000 17027165 21581262 172629 -3850384 1225000 16678507 17837624 3743638 21581262 19190328 157296 1510000 17837624 0.97460 0.02100 0.00440 0 0 16287 10471 5816 5816 LEASE LIABILITY - OPERATING 148121 148121 X 8744753 3791571 48717 3840288 4904465 42831 -5267 37564 4942029 5236046 0 5236046 42831 -5267 37564 5273610 PART V, LINE 4: THE ASSOCIATION ESTABLISHED A RESERVE TO FUND FUTURE OPERATIONS AND AN ENDOWMENT FUND FOR RESEARCH AND PATIENT SERVICES. IN 2022, THE ASSOCIATION ESTABLISHED AN ENDOWMENT FUND AND RECEIVED CERTAIN GIFTS FROM THE DONOR TO BE MAINTAINED IN PERPETUITY. PART X, LINE 2: THE ASSOCIATION QUALIFIES AS A TAX-EXEMPT ORGANIZATION UNDER SECTION 501(C)(3) OF THE INTERNAL REVENUE CODE AND, THEREFORE, HAS NO PROVISION FOR FEDERAL INCOME TAXES. IT IS ALSO EXEMPT FROM STATE INCOME TAX UNDER THE ILLINOIS CHARITABLE TRUST ACT. THE ASSOCIATION FOLLOWS THE GUIDANCE OF ACCOUNTING STANDARDS CODIFICATION (ASC) 740, ACCOUNTING FOR INCOME TAXES, RELATED TO UNCERTAINTIES IN INCOME TAXES, WHICH PRESCRIBES A THRESHOLD OF MORE LIKELY THAN NOT FOR RECOGNITION AND DERECOGNITION OF TAX POSITIONS TAKEN OR EXPECTED TO BE TAKEN IN A TAX RETURN. THERE ARE NO SUCH UNCERTAIN TAX POSITIONS FOR THE ASSOCIATION FOR THE YEARS ENDED OCTOBER 31, 2024 AND 2023. PART XI, LINE 2D - OTHER ADJUSTMENTS: CHANGE IN VALUE - SPLIT INTEREST AGREEMENT 48,717. PART XI, LINE 4B - OTHER ADJUSTMENTS: COST OF GOODS SOLD -5,267. PART XII, LINE 4B - OTHER ADJUSTMENTS: COST OF GOODS SOLD -5,267. EUROPE (INCLUDING ICELAND & GREENLAND) - ALBANIA, ANDORRA, AUSTRIA, BELGIUM 0 0 PROGRAM SERVICES INTERNATIONAL KIDNEY CANCER SYMPOSIUM 264456 0 0 0 0 0 0 264456 0 264456 0 0 0 0 0 0 1 CLEVELAND CLINIC FOUNDATION PO BOX 931517 CLEVELAND OH 44193 340714585 501(C)3 75000 0 N/A N/A RESEARCH FRED HUTCHINSON CANCER CENTER 1100 FAIRVIEW AVENUE NORTH SEATTLE WA 98109 911935159 501(C)3 75000 0 N/A N/A RESEARCH H LEE MOFFIT CANCER CENTER & RESEARCH INSTITUTE 12902 MAGNOLIA DRIVE TAMPA FL 33612 592451713 501(C)3 75000 0 N/A N/A RESEARCH JOHNS HOPKINS UNIVERSITY 3400 NORTH CHARLES STREET SAN MARTIN CENTER BALTIMORE MD 21218 520595110 501(C)3 75000 0 N/A N/A RESEARCH THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER 1515 HOLCOMBE BOULEVARD UNIT 1676 HOUSTON TX 770304009 746001118 UNIVERSITY OF TEXAS 75000 0 N/A N/A RESEARCH 5 PATIENT ASSISTANCE VISA GIFT CARDS 120 12698 N/A N/A PART I, LINE 2: THE GRANT REVIEW PROCESS THOROUGHLY VETS GRANT APPLICANTS. IF SELECTED TO RECEIVE A KCA RESEARCH GRANT, THE GRANTEE MUST SIGN A KCA GRANT ACCEPTANCE AGREEMENT TERMS AND CONDITIONS. THIS AGREEMENT REQUIRES THE GRANTEE TO SUBMIT A GRANT PROGRESS REPORT WITH OUTCOMES, POSSIBLE FUTURE RESEARCH DIRECTIONS, REFLECTIVE IMPACT STATEMENT, AND AN ACCOUNTING OF HOW THE GRANT FUNDS WERE USED. THROUGH OUR PATIENT ASSISTANCE FUND, WE HELP KIDNEY CANCER PATIENTS OFFSET COSTS THEY INCUR WHEN GETTING TREATMENT LIKE PARKING, MEALS, ETC. WE SEND THEM A KCA BRANDED VISA GIFT CARD IN EITHER A $50 OR $250 AMOUNT BASED ON THEIR NEED. WE ALSO WORK DIRECTLY WITH TREATMENT FACILITIES TO PROVIDE $25 KCA BRANDED VISA GIFT CARDS TO KIDNEY CANCER PATIENTS WHILE THEY ARE AT THE FACILITY RECEIVING TREATMENT. X X X 0 0 0 0 0 0 0 0 0 GRETCHEN VAUGHAN PRESIDENT & CEO 270984 0 67568 0 1200 0 15814 0 11037 0 366603 0 0 0 KENDALL MONROE CHIEF ADVANCEMENT OFFICER 216926 0 20045 0 1407 0 11525 0 17013 0 266916 0 0 0 SALVATORE LA ROSA CHIEF SCIENTIFIC OFFICER 190800 0 21438 0 939 0 8218 0 8962 0 230357 0 0 0 LARANDA BURKE CHIEF FINANCIAL OFFICER 179004 0 16200 0 2196 0 11525 0 13757 0 222682 0 0 0 FORM 990, PART VI, SECTION A, LINE 8B THE ORGANIZATION DOES NOT HAVE A COMMITTEE WITH AUTHORITY TO ACT ON BEHALF OF THE GOVERNING BODY. FORM 990, PART VI, SECTION B, LINE 11B THE 990 IS REVIEWED IN DETAIL BY THE CHIEF FINANCIAL AND OPERATING OFFICER AND THE PRESIDENT/CEO BEFORE SIGNING. THE RETURN IS MADE AVAILABLE TO THE FULL BOARD OF DIRECTORS TO REVIEW VIA EMAIL BEFORE IT IS FILED. FORM 990, PART VI, SECTION B, LINE 12C THE ORGANIZATION HAS A WRITTEN CONFLICT OF INTEREST POLICY THAT REQUIRES EMPLOYEES AND BOARD MEMBERS TO ANNUALLY DISCLOSE INTERESTS THAT COULD GIVE RISE TO CONFLICTS. AT THE NOVEMBER BOARD MEETING, EVERY BOARD MEMBER IS REQUIRED TO COMPLETE A CONFLICT OF INTEREST QUESTIONNAIRE ACKNOWLEDGING THEY UNDERSTAND THE POLICY AND DISCLOSING ANY CONFLICTS OF INTEREST THEY ARE AWARE OF. THROUGHOUT THE YEAR, SIGNIFICANT CONTRACTS AND TRANSACTIONS ARE REVIEWED BY THE CHIEF FINANCIAL AND OPERATING OFFICER AND THE PRESIDENT/CEO FOR POTENTIAL CONFLICTS. IF AN ACTUAL OR POTENTIAL CONFLICT IS IDENTIFIED, THE ASSOCIATION ACQUIRES AT LEAST TWO OTHER QUOTES TO PRESENT TO THE FINANCE COMMITTEE FOR APPROVAL PRIOR TO RATIFYING WITH THE BOARD OF DIRECTORS. THE CONFLICTED MEMBER IS RECUSED FROM VOTING ON MATTERS IN WHICH THE CONFLICT IS IDENTIFIED. FORM 990, PART VI, SECTION B, LINE 15 THE BOARD CHAIR AND THE NOMINATING AND GOVERNANCE COMMITTEE (NGC) IS RESPONSIBLE FOR ADMINISTERING THE ANNUAL PERFORMANCE EVALUATION OF THE PRESIDENT/CEO. THE NGC REVIEWS COMPENSATION DATA THAT IS AVAILABLE ON SITES LIKE CHARITY NAVIGATOR AND GUIDESTAR AS WELL AS THE 990 RETURNS OF SIMILAR NONPROFIT ORGANIZATIONS. THE NGC MAKES A RECOMMENDATION TO THE BOARD AND THE BOARD VOTES ON THE COMPENSATION OF THE PRESIDENT/CEO. THE PRESIDENT/CEO, CHIEF ADVANCEMENT OFFICER, CHIEF SCIENTIFIC OFFICER, DIRECTOR OF OPERATIONS, AND CHIEF FINANCIAL AND OPERATING OFFICER WORKED TOGETHER TO REVIEW THE MERIT INCREASES AND BONUSES OF THE STAFF. THE FACTORS CONSIDERED IN AWARDING INCREASES WAS PERFORMANCE REVIEW RATING, ACCOMPLISHMENT OF GOALS, LENGTH OF SERVICE, ANY RECENT PROMOTIONS, AND THE APPROVED ANNUAL BUDGET. THE PROCESS DESCRIBED HERE WAS LAST COMPLETED IN 2024. FORM 990, PART VI, SECTION C, LINE 19 THE ORGANIZATION MAKES ITS BY-LAWS, CONFLICT OF INTEREST POLICY AND FINANCIAL STATEMENTS AVAILABLE TO THE GENERAL PUBLIC UPON REQUEST. FORM 990, PART IX, LINE 11G OTHER PROFESSIONAL FEES: PROGRAM SERVICE EXPENSES 343,699. MANAGEMENT AND GENERAL EXPENSES 151,094. FUNDRAISING EXPENSES 35,923. TOTAL EXPENSES 530,716. FORM 990, PART XI, LINE 9: CHANGE IN VALUE - SPLIT INTEREST AGREEMENT 48,717.